N,N-二乙基-2-甲氧基乙酰胺 | 70814-00-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N,N-二乙基-2-甲氧基乙酰胺
• 英文名称: N,N-Diethyl-α-methoxy-acetamid
• 英文别名: N,N-Dimethylmethoxyacetamid；2-methoxy-N,N-diethyl-acetamide；N,N-Diethyl-2-methoxyacetamide
• CAS: 70814-00-5
• 化学式: C₇H₁₅NO₂
• mdl: MFCD07787524
• 分子量: 145.202
• InChiKey: KMWNUXUPCAAAES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  甲醇 、 N,N-diethyl-2-diazoacetamide 生成 N,N-二乙基-2-甲氧基乙酰胺
  参考文献：
  名称：

  Conformational and medium effects on intramolecular carbene reactions

  摘要：

  DOI：

  10.1021/ja00760a033

文献信息

• [EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE ET LEURS MÉTHODES D'UTILISATION
  申请人：CALICO LIFE SCIENCES LLC

  公开号：WO2021127499A1

  公开（公告）日：2021-06-24

  Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g, protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g, a cancer or a metabolic disease.

  本文提供了用于抑制蛋白酪氨酸磷酸酶的化合物、组合物和方法，例如蛋白酪氨酸磷酸酶非受体型2（PTPN2）和/或蛋白酪氨酸磷酸酶非受体型1（PTPN1），以及用于治疗对PTPN1或PTPN2抑制剂治疗有良好反应的相关疾病、紊乱和状况的方法，例如癌症或代谢性疾病。
• Ultrafast Time-Resolved Infrared Spectroscopy Study of the Photochemistry of <i>N</i>,<i>N</i>-Diethyldiazoacetamide: Rearrangement in the Excited State
  作者：Yunlong Zhang、Gotard Burdziński、Jacek Kubicki、Matthew S. Platz

  DOI：10.1021/ja904009x

  日期：2009.7.22

  beta-lactam is formed immediately after the laser pulse but gamma-lactam is formed from both slow and fast processes. It is concluded that beta-lactam is formed from the diazoamide excited state via the rearrangement in the excited state (RIES) mechanism and that gamma-lactam is formed from both RIES and carbene. In methanol, both carbene decay and the rise of amide ether product are observed directly. Predictions

  超快红外光谱表明，在氯仿中，β-内酰胺在激光脉冲后立即形成，而 γ-内酰胺则由慢速和快速过程形成。得出的结论是，β-内酰胺是通过激发态重排 (RIES) 机制从重氮酰胺激发态形成的，γ-内酰胺是由 RIES 和卡宾形成的。在甲醇中，直接观察到卡宾衰变和酰胺醚产物的上升。密度泛函理论计算的预测与这些观察结果一致。
• Bismaleamic acid, bismaleimide and cured product thereof
  申请人：Uera Kazuyoshi

  公开号：US20090312519A1

  公开（公告）日：2009-12-17

  A bismaleamic acid obtained by reacting a bifunctional phenylene ether oligomer diamine, obtained by introducing aromatic amino groups into both terminals of a specific bifunctional phenylene ether oligomer, with maleic anhydride, a bismaleimide obtained from the bismaleamic acid as a raw material, which bismaleimide has high heat resistance, low dielectric characteristics and excellent solvent solubility and exhibits only a small change in dielectric characteristics even in high humidity, a curable resin composition containing the above bismaleimide and a cured product obtained by curing the curable resin composition.

  通过将具有芳香族氨基团的双官能苯醚寡聚二胺与马来酸酐反应获得的双马来酰胺酸，再以该双马来酰胺酸为原料制备的双马来酰亚胺，该双马来酰亚胺具有高耐热性、低介电特性和优异的溶剂溶解性，即使在高湿度条件下也仅表现出微小的介电特性变化，以及包含上述双马来亚胺的可固化树脂组合物和通过固化可固化树脂组合物获得的固化产物。
• Modulators of muscarinic receptors
  申请人：Davies Robert

  公开号：US20070213315A1

  公开（公告）日：2007-09-13

  The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

  本发明涉及毒蕈碱受体调节剂。本发明还提供包含此类调节剂的组合物，并使用这些方法治疗毒蕈碱受体介导的疾病。
• Inhibitors of microsomal triglyceride transfer protein and apo-B secretion
  申请人：Bartolozzi Alessandra

  公开号：US20070027183A1

  公开（公告）日：2007-02-01

  The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to pharmaceutical compositions comprising the compounds and to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.

  本发明涉及一种抑制微粒体三酰甘油转移蛋白和/或载脂蛋白B（Apo B）分泌的化合物。这些化合物可用于预防和治疗各种疾病，特别是动脉粥样硬化及其临床后遗症，降低血清脂质和相关疾病。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗高三酰甘油血症、高乳糜微粒血症、动脉粥样硬化、肥胖症和相关疾病的方法。本发明还提供了一种减少载脂蛋白B（apo B）分泌的方法。